OPUS 4 | Search

17 search hits

1 to 17

Sort by

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment (2018)

Stosch, Juliane M. ; Heumüller, Anezka ; Niemöller, Christoph ; Bleul, Sabine ; Rothenberg-Thurley, Maja ; Riba, Julian ; Renz, Nathalie ; Szarc vel Szic, Katarzyna ; Pfeifer, Dietmar ; Follo, Marie ; Pahl, Heike L. ; Zimmermann, Stefan ; Duyster, Justus ; Wehrle, Julius ; Lübbert, Michael ; Metzeler, Klaus H. ; Claus, Rainer ; Becker, Heiko

Sunitinib in the treatment of thymoma and associated autoimmune neutropenia (2017)

Becker, Heiko ; Auman, Konrad ; Claus, Rainer ; von Bubnoff, Nikolas ; Sachs, Ulrich J. ; Waller, Cornelius F.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia (2017)

Yalcin, Arzu ; Kovarbasic, Marlon ; Wehrle, Julius ; Claus, Rainer ; Becker, Heiko ; Abdelkarim, Mahmoud ; Gaidzik, Verena I. ; Schmidts, Andrea ; Wäsch, Ralph ; Pahl, Heike L. ; Döhner, Konstanze ; Bullinger, Lars ; Duyster, Justus ; Lübbert, Michael ; Hackanson, Björn

Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine) (2017)

Lübbert, Michael ; Ihorst, Gabriele ; Sander, Philipp N. ; Bogatyreva, Ljudmila ; Becker, Heiko ; Wijermans, Pierre W. ; Suciu, Stefan ; Bissé, Emmanuel ; Claus, Rainer

Molecular genetic characterization of individual cancer cells isolated via single-cell printing (2016)

Riba, Julian ; Renz, Nathalie ; Niemöller, Christoph ; Bleul, Sabine ; Pfeifer, Dietmar ; Stosch, Juliane M. ; Metzeler, Klaus H. ; Hackanson, Björn ; Lübbert, Michael ; Duyster, Justus ; Koltay, Peter ; Zengerle, Roland ; Claus, Rainer ; Zimmermann, Stefan ; Becker, Heiko

Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis (2016)

Niemöller, Christoph ; Renz, Nathalie ; Bleul, Sabine ; Blagitko-Dorfs, Nadja ; Greil, Christine ; Yoshida, Kenichi ; Pfeifer, Dietmar ; Follo, Marie ; Duyster, Justus ; Claus, Rainer ; Ogawa, Seishi ; Lübbert, Michael ; Becker, Heiko

Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction (2021)

Niemöller, Christoph ; Wehrle, Julius ; Riba, Julian ; Claus, Rainer ; Renz, Nathalie ; Rhein, Janika ; Bleul, Sabine ; Stosch, Juliane M. ; Duyster, Justus ; Plass, Christoph ; Lutsik, Pavlo ; Lipka, Daniel B. ; Lübbert, Michael ; Becker, Heiko

Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 × 2, phase II trial (2020)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia (2020)

Becker, Heiko ; Pfeifer, Dietmar ; Ihorst, Gabriele ; Pantic, Milena ; Wehrle, Julius ; Rüter, Björn H. ; Bullinger, Lars ; Hackanson, Björn ; Germing, Ulrich ; Kuendgen, Andrea ; Platzbecker, Uwe ; Döhner, Konstanze ; Ganser, Arnold ; Hagemeijer, Anne ; Wijermans, Pierre W. ; Döhner, Hartmut ; Duyster, Justus ; Lübbert, Michael

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome (2019)

Stomper, Julia ; Ihorst, Gabriele ; Suciu, Stefan ; Sander, Philipp N. ; Becker, Heiko ; Wijermans, Pierre W. ; Plass, Christoph ; Weichenhan, Dieter ; Bissé, Emmanuel ; Claus, Rainer ; Lübbert, Michael

Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine (2025)

In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse-risk genetics, without adding toxicity. We performed a post hoc analysis to determine the predictive impact of TP53 status. Despite a nominally higher ORR, the clinically meaningful survival benefit when adding ATRA to DEC was diminished, but not completely negated, in TP53-mutated patients. Indeed, 2 out of 14 TP53-mutated patients (14%) randomized to a DEC + ATRA-containing regimen lived for > 36 months. Further studies of ATRA combined with hypomethylating agents appear warranted in non-M3 AML patients ineligible for HMA/venetoclax therapy.

Randomized phase II study of all-trans retinoic acid and valproic acid added to decitabine in newly diagnosed elderly AML patients (DECIDER trial): predictive impact of TP53 status [Abstract] (2021)

Fetal hemoglobin (HbF) induction during initial decitabine (DAC) treatment of elderly high-risk MDS and AML patients: a potential dynamic biomarker for outcome [Abstract] (2017)

Stomper, Julia ; Ihorst, Gabriele ; Suciu, Stefan ; Sander, Philipp Nikolaus ; Becker, Heiko ; Wijermans, P. W. ; Bissé, Emmanuel ; Claus, Rainer ; Lübbert, Michael

Activity of Decitabine (DAC) combined with All-Trans Retinoic Acid (ATRA) in oligoblastic AML: subgroup analysis of a randomized 2x2 phase II trial [Abstract] (2020)

1 to 17